A randomized trial published in the New England Journal of Medicine evaluated the effects of infrequent administration of zoledronate in early postmenopausal women over a decade. The study revealed that zoledronate administered at baseline and 5 years effectively reduced morphometric vertebral fractures, fragility fractures, any fractures, and major osteoporotic fractures. Lead study author Mark J. Bolland, MB, ChB, PhD, highlighted the long-lasting effects on bone density and turnover, emphasizing the practical, long-term intervention for vertebral fracture prevention in this population.